RhoVac Past Earnings Performance

Past criteria checks 0/6

RhoVac's earnings have been declining at an average annual rate of -30.7%, while the Biotechs industry saw earnings growing at 2.5% annually.

Key information

-30.7%

Earnings growth rate

-12.2%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth raten/a
Return on equity-393.7%
Net Marginn/a
Next Earnings Update27 Feb 2023

Recent past performance updates

Recent updates

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

Feb 12
We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Aug 27
RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Mar 23
Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Dec 08
We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Revenue & Expenses Breakdown
Beta

How RhoVac makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:RHOVAC Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 220-50620
30 Jun 220-68770
31 Mar 220-60750
31 Dec 210-55720
30 Sep 210-49670
30 Jun 210-44620
31 Mar 210-43580
31 Dec 200-40530
30 Sep 200-24780
30 Jun 200-23660
31 Mar 200-35460
31 Dec 190-34420
30 Sep 190-42100
30 Jun 190-37130
31 Mar 190-20220
31 Dec 180-17200
30 Sep 180-14160
30 Jun 180-13150
31 Mar 180-12140
31 Dec 170-11130
30 Sep 170-12150
30 Jun 170-12140
31 Mar 170-12130
31 Dec 160-11130
30 Sep 160-9100
30 Jun 160-660

Quality Earnings: RHOVAC is currently unprofitable.

Growing Profit Margin: RHOVAC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RHOVAC is unprofitable, and losses have increased over the past 5 years at a rate of 30.7% per year.

Accelerating Growth: Unable to compare RHOVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RHOVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.9%).


Return on Equity

High ROE: RHOVAC has a negative Return on Equity (-393.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.